BOLD (Boundless Bio) Company Cash Volume

Corporate company logo of Boundless Bio (BOLD)

Boundless Bio, Inc. (BOLD) free cash flow helps assess its leadership strategy in the ecDNA therapy niche and its patent protection. This chart confirms management's adaptation following the IPO and support from funds, as well as the monetization of the platform for collaborations with pharma behemoths. Meanwhile, 0.06 becomes the new value for this metric, demonstrating a financial cushion for development without the issuance of new shares.

Company Cash and Cash Equivalents: Boundless Bio Inc. (BOLD) for 03/29/2024 - 11/21/2026

Analytical breakdowns and data insights for company Boundless Bio (BOLD)

- current price and projected stock value:
General company analysis:BOLD Boundless Bio Inc.
Product sample of boundlessbio.com

This indicator measures the issuer's volume of own liquid assets, reflecting its ability to fund operating activities without debt burdens or external borrowings. By analyzing the cash reserves chart, an investor assesses the financial autonomy of Boundless Bio, Inc. (BOLD), which is critical for sustaining costly ecDNA-based cancer therapy developments until the company reaches the stage of positive free cash flow.

Competitors of Boundless Bio, Inc. (BOLD)

Company Cash Volume TEM|QGEN - Company Cash Reserve|ionispharma.com - Company Cash on Hand|Company Cash Balance RGEN|Avidity Corp - Company Cash Volume|CRISPR Therapeutics Corp - Company Total Cash Amount|GeneDx Holdings (WGS) - Company Cash Funds|Ultragenyx Pharmaceutical (RARE) - Company Cash Volume|Company Cash on Hand BEAM|Sarepta (SRPT) - Company Liquid Assets|Company Cash Funds Twist Bioscience Corp (TWST)|10x - Company Cash and Cash Equivalents|Company Cash Volume NTLA (intelliatx.com)|Company Total Cash Amount STOK (stoketherapeutics.com)|BioLife Solutions Inc - Company Cash Volume|WVE (Wave Life Sciences Ltd) - Company Cash and Cash Equivalents|Maze Therapeutics Corp (MAZE) - Company Cash Funds|Company Cash and Cash Equivalents SION|PRME (Prime Medicine Inc) - Company Cash Volume|Taysha Gene Therapies (TSHA) - Company Liquid Assets|Company Cash on Hand QURE (uniqure.com)|Company Total Cash Amount MGTX|Company Cash Volume RGNX (regenxbio.com)|SLDB: Company Cash and Cash Equivalents|ocugen.com - Company Cash Volume|PACB - Company Cash Volume|BNTC: Company Cash Volume|Company Cash and Cash Equivalents DSGN|Company Cash Funds Rocket Pharmaceuticals|Company Cash on Hand 4DMT (FDMT)|Company Cash Volume LXEO|Company Liquid Assets Korro Bio Inc.|Company Cash Volume EDIT (Editas Medicine Inc)|SLN: Company Cash and Cash Equivalents|PRQR - Company Cash Funds|Company Liquid Assets codexis.com CDXS|SGMO: Company Cash Volume|Nautilus Biotechnology (NAUT) - Company Cash Volume|Company Cash Funds Metagenomi, Inc|precisionbiosciences.com (DTIL) - Company Liquid Assets|Company Cash Funds Generation Bio Co. (GBIO)|Company Cash Volume Exicure Inc. (XCUR)|Company Cash Funds imunon.com IMNN|Company Cash Volume Phio Pharmaceuticals PHIO|Mustang Bio Inc - Company Cash Volume|Company Cash Reserve transcodetherapeutics.com|BNGO: Company Cash Volume|Company Cash and Cash Equivalents APDN|BLUE (bluebirdbio.com) - Company Cash Volume|Company Cash Reserve ImmunoPrecise Antibodies IPA|Company Cash on Hand OMGA (omegatherapeutics.com)|Company Cash Volume Singular Genomics Systems, Inc. (OMIC)|Company Cash Volume RGLS (Regulus Therapeutics, Inc.)|Company Cash Volume Syros SYRS|Telesis Bio, Inc. - Company Cash Volume|TRACON Pharmaceuticals (TCON) - Company Cash on Hand|UBX: Company Cash Volume